Genomic Biomarkers for Personalized Medicine in Breast Cancer
Journal: International Journal of Clinical Pharmacology & Toxicology (IJCPT) (Vol.01, No. 01)Publication Date: 2012-10-01
Authors : Minjun Chen; Huixiao Hong; Weida Tong;
Page : 35-37
Keywords : Genomic Biomarkers; Personalized Medicine; Breast Cancer;
Abstract
Breast cancer is the most common malignant disease in Western women. Historically, breast cancer was perceived as a single disease with various clinicalpathological features, and therefore, “one drug fits all” approaches drove the treatment regimens. The advent of genomics studies has led to a new paradigm in which breast cancer is heterogeneous consisting of different diseases from the same organ site. For example, gene expression profiling analysis revealed that estrogen receptor (ER)-positive and ERnegative breast cancer are two distinct diseases with different risk factors, clinical presentations, outcomes, and responses to systemic therapies. Consequently, the new paradigm demands a personalized strategy in cancer medicine, in which the selection of treatment regimens for each cancer patient will largely rely on assessment by predictive biomarkers and study of the anatomical and pathological features of the cancer.
Other Latest Articles
- Drug-Induced Delirium from a Suspected Drug-Drug Interaction between Promethazine and Ketorolac
- Steady State Plasma Levels of Bupropion After Administration of 3x150 Mg Extended Release Reference Tablets and Switching to 1x450 Mg Extended Release 450ER Tablets
- Current Pharmacological and Non-Pharmacological Treatments of Panic Disorder/Agoraphobia
- AT2 receptor: Its role in obesity associated hypertension
- Assessment of Fatigue and Its Associated Factors in Breast Cancer Patients Under Treatment
Last modified: 2015-07-18 13:42:29